CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CVRX 12.23.2024
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rdAnnual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website atir.cvrx.com.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the BarostimTM System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visitwww.cvrx.com.
Investor Contact:
Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.com
Media Contact:
Laura O’NeillFinn Partners402-499-8203laura.oneill@finnpartners.com
